Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. reports developments across its orthopedic and spine medical technology portfolio. The company provides spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System, for complex musculoskeletal conditions.
Recurring OFIX news includes quarterly results, guidance, product launches and commercial execution in Spine and Orthopedics. Company updates also cover pediatric limb reconstruction offerings such as FITBONE, planning software such as OrthoNext, the TRUELOK Elevate system, spine leadership realignment, distributor transitions, biologics activity and the discontinued M6 artificial disc product lines.
Orthofix Medical Inc. (NASDAQ:OFIX) announced significant findings from a retrospective study published in The International Journal of Spine Surgery, highlighting a 92.7% fusion rate for patients undergoing three- and four-level lumbar arthrodesis surgery with the SpinalStim device. This data, gathered from 55 patients, reinforces the effectiveness of Pulsed Electromagnetic Field Stimulation (PEMF) therapy even among high-risk patients. The device is FDA-approved for lumbar spinal fusion procedures and is supported by the STIM onTrack mobile app, enhancing patient engagement in recovery.
Orthofix Medical Inc (NASDAQ: OFIX) has launched the FORZA Ti PLIF Spacer System in the U.S., designed for enhancing Posterior Lumbar Interbody Fusion (PLIF) procedures. The device is 3D-printed with optimized porosity and features to support bone ingrowth, critical for surgical success. Key features include a large graft window, titanium endplates with 400 micron pores, and a functional gradient porous structure. The FORZA Ti system is part of Orthofix's growing portfolio of innovative 3D-printed titanium products aimed at improving surgical outcomes.
Orthofix Medical, a global medical device company focused on spine and orthopedics, announced that CEO Jon Serbousek and CFO Doug Rice will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2021, at 11:00 a.m. ET. The virtual event will include one-on-one meetings and a live audio webcast available on the Company’s website for interested stakeholders.
Orthofix aims to deliver innovative solutions to enhance patient mobility and distributes its products in over 60 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. CEO Jon Serbousek and CFO Doug Rice will lead the discussion. The chat will be followed by one-on-one meetings. A live audio webcast can be accessed on the Company's website.
Orthofix specializes in innovative medical devices and biologics for spine and orthopedics, aiming to enhance patient mobility. Its products are distributed in over 70 countries from its headquarters in Lewisville, Texas.
Orthofix Medical Inc. (NASDAQ: OFIX) continues its sponsorship of Olympic Gold Medalist Laura Wilkinson as she trains for the Tokyo Olympics. Wilkinson, a three-time U.S. Olympic diver, overcame cervical disc degeneration with a successful spine fusion using Orthofix technology. At 39, she returned to diving, aiming to compete in the U.S. Olympic Team Trials from June 6-13, 2021. Orthofix's mission centers on improving patient mobility, and they express pride in supporting Wilkinson's journey while promoting awareness about spine health.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the OSCAR PRO Ultrasonic Arthroplasty Revision System in the U.S. and Europe. This advanced system aims to improve joint revision surgeries by effectively removing cement from failed implants, addressing challenges faced with traditional methods. As the fourth generation of the OSCAR line, it features an enhanced user interface and new data collection capabilities. The system is significant for the treatment of failed joint replacements, which may require surgical intervention due to cement adhesion.
Orthofix Medical Inc (NASDAQ:OFIX) announced positive preliminary results from the three- and four-year follow-up of its M6-C artificial cervical disc study. The data will be presented at the ISASS annual meeting on May 14. Key findings include a mean Neck Disability Index (NDI) score of 10.9 at three years and 10.3 at four years for M6-C patients, compared to 17.2 and 19.2 for the ACDF group, respectively. The study highlights statistically significant pain score improvements in neck and shoulder/arm pain. The M6-C disc, approved by the FDA in 2019, validates the benefits of cervical disc arthroplasty.
Orthofix Medical announced FDA 510(k) clearance for its OrthoNext digital platform, designed for deformity analysis and preoperative planning in pediatric orthopedic procedures. This platform complements the JuniOrtho Plating System, which targets advanced deformity and trauma reconstruction for pediatric patients. The company is progressing with a full market launch of the JuniOrtho system in the U.S. and Europe. This innovative combination aims to enhance surgical planning and optimize patient outcomes in pediatric orthopedic care.
Orthofix Medical reported Q1 2021 net sales of $105.6 million, reflecting a 0.7% increase year-over-year. The company faced challenges from the pandemic and severe weather, resulting in a net loss of $(5.8) million or $(0.30) EPS. Adjusted EPS was $0.17, up from $0.09 in Q1 2020. Gross profit decreased to $79.7 million with a gross margin of 75.5%. Liquidity remains stable with $95.1 million in cash. The company anticipates 2021 net sales of $455 million to $465 million, marking a projected 11.9% to 14.4% increase.
Orthofix Medical Inc. (NASDAQ:OFIX) has entered into an exclusive license agreement with IGEA S.p.A to commercialize innovative orthopedic products in the U.S. and Canada. This includes obtaining FDA approvals for IGEA's bone and cartilage stimulation technologies, enhancing Orthofix's existing Pulsed Electromagnetic Field (PEMF) therapies. The collaboration aims to expand treatment options for fracture management and improve joint health. IGEA has a strong presence in Europe, treating over 20,000 patients annually, and this partnership will leverage both companies' strengths in the medical device market.